CVS · Q2 2025 Earnings
CautiousCVS Health
Reported July 31, 2025
30-second summary
Revenue grew 8.4% to $98.9B with adjusted EPS of $1.81 and adjusted operating income of $3.81B, driven by a $370M YoY HCB earnings improvement and a stabilizing pharmacy reimbursement environment. Management raised FY adjusted EPS to $6.30–$6.40 (from $6.00–$6.20) and operating cash flow to at least $7.5B (from ~$7.0B), but GAAP EPS guidance was cut to $3.84–$3.94 from $4.23–$4.43 — a divergence that signals one-time charges (notably a $470M Group MA premium deficiency reserve) absorbed against an otherwise improving underlying run-rate. Q&A made clear that Group MA margin recovery is a multi-cycle effort, not a single repricing fix.
Headline numbers
EPS
Q2 FY2025
$1.81
Revenue
Q2 FY2025
$98.92B
+8.4% YoY
Operating margin
Q2 FY2025
2.4%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $98.92B | +8.4% |
| EPS | $1.81 | — |
| Operating margin | 2.4% | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| Health Care Benefits | $36.258B | +11.6% |
| Health Services | $46.453B | +10.2% |
| Pharmacy & Consumer Wellness | $33.581B | +12.5% |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| Medical Benefit Ratio (MBR) | 89.9% |
| Medical Membership | 26.7 million |
| Pharmacy Claims Processed (30-day equivalent) | 469.0 million |
| Prescriptions Filled (30-day equivalent) | 438.1 million |
| Same Store Prescription Volume Growth | 6.4% |
| Days Claims Payable | 40.9 days |
| Adjusted Operating Income | $3.808 billion |
| Operating Cash Flow (YTD) | $6.5 billion |
Management tone
The press release leans on phrases like "significant and durable recovery at Aetna" and "strong retention at CVS Caremark" — language that is firmer than the cautious framing CVS used through 2024 when the Medicare Advantage trend shock dominated the narrative. Management is now willing to call the Aetna trajectory a recovery, not just a stabilization.
That said, in Q&A Steve Nelson explicitly framed Group MA margin recovery as something that "sometimes takes more than one cycle," with ~50% of Group MA revenue up for renewal in 2026 and a $470M PDR booked this quarter. The willingness to put a multi-cycle timeline on the table — rather than promising a single-renewal fix — is a credibility-positive shift but also an acknowledgment that the bottom of this segment's margin trough may not be fully behind them.
On PCW, the tonal shift is sharper: management moved from defending pharmacy economics to pointing at a structural inflection. Brian Newman quantified the reimbursement guide improving from "down 5% to down 1.6%" YTD, and Prem Shah attributed it to CostVantage commercial rollout being complete plus competitor closures driving share gains. The framing is no longer "managing decline" but "executing on a turnaround" — though management still flagged consumer dynamics and vaccine demand as wild cards.
Q&A highlights
Lisa Gill · JP Morgan
Asked about visibility, underlying assumptions, and conviction in HCB guidance for back half of year given strong Q2 performance, $600M beat, and multiple moving parts.
Management highlighted Aetna as top enterprise priority with multi-year recovery focus. David emphasized progress and innovation initiatives (prior authorizations, bundled PA process). Brian detailed Q2 earnings beat of $370M YoY, noted elevated medical cost trends were modestly favorable in aggregate, stripped out one-time items ($300M favorable risk adjustment and net PYD offset by $470M group MA PDR), underlying beat ~$500M driven primarily by Medicare (individual MA, Part D, supplementals). Steve reinforced cautious outlook and multiple operational improvements driving results.
Stephen Baxter · Wells Fargo
Asked where PDR places Group MA margins in 2025 and timeline for repricing the 50% cohort coming due in 2026, including whether single cycle will return to target margins.
Steve Nelson acknowledged contracts are typically 3-5 year agreements and management taking disciplined approach to renewal while contemplating elevated trends. Stated absolute objective is to achieve target margins but sometimes takes more than one cycle. Expressed optimism about Group MA business as important part of enterprise with synergies to Caremark. Emphasized treating it seriously and ensuring it performs at target margins.
George Hill · Deutsche Bank
Asked for breakdown of PCW segment guidance changes including vaccine outlook impact, reimbursement stabilization impact, Rite Aid acquisition impact, and sustainability of performance.
Prem detailed strong PCW performance: $2.5% top line growth, $1.6B AOI increase of 0.6%. Highlighted 4.5% script growth driven by innovation, strong service levels, and market disruption from competitor closures. Noted CVS cost advantage rollout to commercial marketplace with all contracts now on it, tracking to expectations. Front store improving from market disruption and retail share gains. Brian clarified guide moved from down 5% to down 1.6% reimbursement headwind YTD; maintaining caution on consumer dynamics and vaccine demand variance. Emphasized multi-year effort underlying results and technology investments.
Andrew Mark · Barclays
Asked to reconcile favorable Aetna Medicare results against unfavorable Oak Street results; questioned whether pressure is from internal vs external MA members and which cost categories are pressured.
Management explained the two books have different populations and acuity profiles. Aetna is large, diverse; Oak Street is smaller, higher acuity. Aetna members represent minority of Oak Street patients. Not all health plans pulled back benefits to same extent as Aetna. Brian noted elevated trends across MA broadly. Prem detailed Oak Street pressure from elevated medical costs, member mix, more robust benefit offerings. Highlighted four focus areas: strong leadership team, technology stack improvements, clinical solution delivery, and thoughtful center expansion. Reaffirmed commitment to value-based care as critical to strategy despite current headwinds.
Eric Pertscher · Nefron Research
Asked about visibility on health services HBR pressure; requested breakdown of $200M headwind between H1 vs H2 expectations, improvement trajectory, and PBM customer price improvements and retention cost dynamics.
Brian addressed visibility on Oak Street HBR driven by elevated medical costs, member mix, robust benefits partially offset by Signify strength. Stated health services earnings distribution roughly evenly split H1/H2 with slight 4Q tilt. Prem highlighted strong 2026 PBM selling season start with upper 90s retention expected, consistent with historical rates. Emphasized Caremark continuing focused on affordability and cost competition as core value driver, noting strong market traction with GLP-1 formulary competition and biosimilar wins.
What to watch into next quarter
Group MA repricing cadence on the 2026 renewal cohort — management signaled multi-cycle recovery; watch for any disclosure on bid actions, benefit design changes, or further PDR adjustments at Q3.
MBR trajectory — Q2 came in at 89.9%; watch whether H2 holds below 90% as Part D seasonality kicks in, and whether the favorable underlying ~$500M HCB beat is repeatable absent the $300M 2024 risk-adjustment tailwind.
PCW reimbursement run-rate — guide moved from -5% to -1.6% YTD; watch whether the improvement holds into Q3/Q4 as the rest of 2025 commercial contracts cycle and CostVantage's full-year impact emerges.
Oak Street operating economics — elevated medical cost trends and richer supplemental benefits remain a drag; watch for any quantification of mitigation actions (center expansion pace, clinical model changes) and the size of any incremental PDR.
Caremark 2026 selling-season win-loss disclosure — upper-90s retention guided; watch for explicit net new client wins/losses at Q3 to validate the "strong start" framing.
Sources
- CVS Health Q2 2025 press release (SEC 8-K, Exhibit 99.1): https://www.sec.gov/Archives/edgar/data/64803/000006480325000023/cvs_ex99x1q2-25.htm
- CVS Health Q2 2025 earnings call commentary (Q&A excerpts).
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.